Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 11,175 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 3 Clear all
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Theta Burst Stimulation to Promote Motor Re-education in Tetraplegia

NCT03277521
View directory record Official record
Conditions
Quadriplegia/Tetraplegia
Interventions
Intermittent theta burst stimulation
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Therapy Integrated With Mindfulness for Patients With Chronic Pain and Opioid Treatment

NCT05875207
View directory record Official record
Conditions
Chronic Pain, Pain, Musculoskeletal, Opioid Use, Physical Therapy
Interventions
Mindfulness based practice, Control/Standard Physical Therapy
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Gainesville, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 1 Interventional

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

NCT03414736
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

NCT01366534
View directory record Official record
Conditions
Malaria
Interventions
Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01), GSK Biologicals' malaria vaccine 257049 (2 doses), GSK Biologicals' malaria vaccine 257049 (3 doses), Sporozoite challenge
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 19, 2026, 6:04 PM EDT
Terminated Phase 1 Interventional

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

NCT01742793
View directory record Official record
Conditions
Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
Interventions
lenalidomide (Revlimid) and romidepsin (Istodax)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 19, 2026, 6:04 PM EDT
Terminated Phase 3 Interventional Results available

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

NCT01445821
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Peripheral Blood Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, Filgrastim, Fludarabine
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
17 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

NCT02481414
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
PepCan, Candin®
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 4 Interventional

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

NCT00116116
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
efavirenz, stavudine extended release, lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

NCT00477607
View directory record Official record
Conditions
Ototoxicity, Unspecified Adult Solid Tumor
Interventions
alpha-lipoic acid, Audiology, laboratory biomarker analysis, Placebo
Drug · Behavioral · Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 19, 2026, 6:04 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

NCT02466971
View directory record Official record
Conditions
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
Brachytherapy, Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Radiation Therapy, Triapine
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
377
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 253 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Strain Change Study for SARS-CoV-2 rS Vaccines

NCT06409663
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions
NVX-CoV2705 Vaccine
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 19, 2026, 6:04 PM EDT
Terminated Phase 2 Interventional Results available

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
View directory record Official record
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 6:04 PM EDT
Withdrawn Early Phase 1 Interventional

Relapse Prevention in Stimulant Use Disorder

NCT04553263
View directory record Official record
Conditions
Stimulant Use, Relapse, Cognitive Function, ADHD
Interventions
Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

NCT01016730
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
Interventions
Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 3 Interventional

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

NCT00358228
View directory record Official record
Conditions
Smoking Cessation
Interventions
Rimonabant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2010 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

'Levonorgestrel IUD Insertion After D&E Procedure

NCT00475228
View directory record Official record
Conditions
Contraceptive Usage
Interventions
Levonorgestrel IUD
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

NCT04183192
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Interventions
Mepolizumab, Reslizumab, Placebo
Biological
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 19, 2026, 6:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

NCT07216209
View directory record Official record
Conditions
Lung Cancer - Non Small Cell
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Peer Genetic Study

NCT05011799
View directory record Official record
Conditions
Healthy Subject, Prostate Carcinoma
Interventions
Cancer Educational Materials, Questionnaire Administration, Educational Intervention
Behavioral · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
35 Years to 69 Years · Male only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 19, 2026, 6:04 PM EDT
Withdrawn Phase 2 Interventional

Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination

NCT00712621
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Counseling, Written materials
Behavioral
Lead sponsor
American Scitech International
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englishtown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2009 · Synced Oct 19, 2026, 6:04 PM EDT
Completed Not applicable Interventional Results available

Testing a Provider-Level Feedback Intervention to Optimize Postoperative Prescribing

NCT04776928
View directory record Official record
Conditions
Opioid Prescribing
Interventions
Push reports
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 19, 2026, 6:04 PM EDT
Not listed Not applicable Interventional

Priming With tDCS: Expanding the Window of Recovery in Chronic Stroke

NCT03964467
View directory record Official record
Conditions
Upper Extremity Paresis
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 19, 2026, 6:04 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
39
States / cities
La Jolla, California • La Mesa, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 19, 2026, 6:04 PM EDT